Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TIROSINT-SOL vs EUTHYROX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Synthetic levothyroxine (T4) is deiodinated to triiodothyronine (T3), which binds to thyroid hormone receptors, activating gene transcription and increasing cellular metabolism.
Synthetic levothyroxine is a T4 hormone that is converted to T3, binding to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate, cardiac output, and thermogenesis.
Hypothyroidism (all causes, including congenital, primary, secondary, and tertiary),Thyroid-stimulating hormone (TSH) suppression therapy (as an adjunct to surgery and radioiodine therapy for thyroid cancer)
Hypothyroidism (primary, secondary, tertiary),Thyroid-stimulating hormone (TSH) suppression in thyroid cancer,Thyroid hormone replacement therapy in myxedema coma,Off-label: Subclinical hypothyroidism (when TSH >10 m IU/L or with symptoms)
Initial dose 1.6 mcg/kg orally once daily; adjust by 12.5-25 mcg increments every 4-6 weeks based on TSH; typical maintenance 100-125 mcg/day.
Initial adult dose 25-50 mcg orally once daily; titrate by 12.5-25 mcg increments every 4-6 weeks; maintenance dose typically 100-200 mcg daily.
Levothyroxine (T4) terminal half-life: 6–7 days in euthyroid, prolonged in hypothyroidism (9–10 days), shortened in hyperthyroidism (3–4 days). Clinical context: steady-state reached after 4–6 weeks.
Terminal half-life: 6-7 days in euthyroid individuals. Longer in hypothyroidism (9-10 days) and shorter in hyperthyroidism (3-4 days). Clinically, steady-state achieved in 4-6 weeks.
Hepatic metabolism via deiodination (D1, D2, D3 isoenzymes; D2 produces T3), glucuronidation (UGT1A), and sulfation; less than 20% excreted unchanged in feces and urine.
Partially deiodinated to active T3 and inactive reverse T3 (r T3) in liver, kidney, and other tissues. Conjugation with glucuronides and sulfates. Minimal CYP450 involvement.
Renal (biliary/fecal minimal): <20% unchanged in urine; majority metabolized then conjugated and excreted in bile/feces.
Primarily renal (approximately 40-50% as unchanged drug and metabolites), with about 20% fecal elimination via bile. Minor biliary excretion.
>99.9% bound to thyroxine-binding globulin (TBG), transthyretin, and albumin.
>99.9% bound to thyroxine-binding globulin (TBG), transthyretin (TTR), and albumin. Lewothyroxine is the active form.
0.10–0.15 L/kg; reflects distribution into lean tissues and thyroid hormone receptors.
0.10-0.15 L/kg, reflecting distribution primarily into extracellular fluid and tissues with high affinity binding to thyroid hormone receptors.
Oral: 40–80% (fasting, empty stomach). TIROSINT-SOL liquid formulation has higher relative bioavailability (~90%) compared to tablets.
Oral: 50-80% (variable, influenced by food, GI disease, and formulation). IV: 100%.
No dose adjustment required for GFR < 60 m L/min; monitor TSH closely in end-stage renal disease as levothyroxine clearance may be reduced.
No renal adjustment required as levothyroxine is primarily metabolized and excreted in feces. Monitor TSH and free T4 in patients with severe renal impairment.
No specific Child-Pugh based adjustments; monitor TSH closely in severe hepatic impairment as metabolism may be impaired.
No specific Child-Pugh adjustment; however, severe hepatic impairment may reduce T4 to T3 conversion; monitor thyroid function tests.
Neonates: 10-15 mcg/kg/day orally once daily; Children >1 year: 4-5 mcg/kg/day; Adolescents: 2-3 mcg/kg/day; adjust based on TSH and T4.
Weight-based: 0-3 months: 10-15 mcg/kg/day; 3-6 months: 8-10 mcg/kg/day; 6-12 months: 6-8 mcg/kg/day; 1-5 years: 5-6 mcg/kg/day; 6-12 years: 4-5 mcg/kg/day; >12 years: 2-3 mcg/kg/day. Administer orally once daily.
Start at lower dose 25-50 mcg/day orally once daily; adjust by 12.5 mcg increments every 4-6 weeks; target TSH 4-6 m IU/L due to higher risk of cardiac effects.
Elderly patients (especially >65 years) or those with cardiovascular disease: start at 12.5-25 mcg orally once daily; increase by 12.5 mcg every 4-6 weeks; lower maintenance doses often required.
Not for the treatment of obesity or weight loss; ineffective and dangerous at high doses.
Not approved for weight loss. Doses above physiologic requirements may produce serious or life-threatening toxicity, especially when used with sympathomimetic amines.
Cardiac toxicity (arrhythmias, ischemia, palpitations) at high doses; adrenal insufficiency (must be corrected before treatment); worsening angina or congestive heart failure; need for dose adjustment in pregnancy; interactions with warfarin, antidiabetic agents, and other medications.
Cardiovascular effects (angina, arrhythmias, hypertension) in patients with underlying heart disease. Risk of thyrotoxic crisis if dose is excessive. Adrenal insufficiency: adjust corticosteroid dose before starting in patients with adrenal insufficiency. Diabetes mellitus: may increase blood glucose and require adjustment of antidiabetic therapy. Osteoporosis: chronic TSH suppression increases risk of bone loss. Interactions with anticoagulants (warfarin), antidiabetic agents, and SSRIs. Discontinue use for weight loss due to serious toxicity.
Uncorrected adrenal insufficiency; untreated thyrotoxicosis; hypersensitivity to any ingredient; acute myocardial infarction (relative).
Untreated adrenal insufficiency, untreated thyrotoxicosis, acute myocardial infarction, hypersensitivity to any component.
Absorption of levothyroxine is reduced by high-fiber foods, soy products, grapefruit juice, and caffeine. Iron, calcium, aluminum- or magnesium-containing antacids, and bile acid sequestrants also inhibit absorption. Separate ingestion of TIROSINT-SOL from these substances by at least 4 hours.
Levothyroxine absorption is decreased by high-fiber foods (e.g., bran, whole grains), soy products, grapefruit juice, walnuts, and cottonseed meal. Also, calcium-fortified foods and beverages can reduce absorption. Take levothyroxine at least 4 hours apart from these foods. Avoid concomitant ingestion with coffee or milk; if needed, maintain consistency. Caffeine may slightly reduce absorption.
Levothyroxine (TIROSINT-SOL) is FDA Pregnancy Category A. No increased risk of fetal malformations when maternal hypothyroidism is treated. Untreated maternal hypothyroidism is associated with increased risks of miscarriage, gestational hypertension, placental abruption, and impaired fetal neurodevelopment. Adequate maternal thyroid hormone levels are critical for fetal brain development, particularly in the first trimester before fetal thyroid function begins.
EUTHYROX (levothyroxine) is a thyroid hormone replacement. Maternal hypothyroidism itself carries significant risks to the fetus, including neurodevelopmental deficits, preterm birth, and low birth weight. The drug does not cross the placenta significantly; fetal thyroid function is independent. No known teratogenic effects from levothyroxine at therapeutic doses. First trimester: essential for maternal euthyroidism to prevent fetal neurodevelopmental impairment. Second and third trimesters: maintenance of maternal euthyroidism supports normal fetal growth and development. Insufficient treatment increases risks.
Levothyroxine is secreted into breast milk in minimal amounts (M/P ratio approximately 2.2). Doses up to 300 mcg/day produce negligible serum levothyroxine levels in breastfed infants. No adverse effects reported. Breastfeeding is considered safe with continued maternal therapy. Monitor infant thyroid function if maternal dose is very high.
Levothyroxine is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.5. It is generally considered compatible with breastfeeding at therapeutic doses as it does not pose a risk to the infant. Monitoring infant thyroid function is not routinely required unless maternal dose is very high or infant shows symptoms.
Pregnancy increases levothyroxine requirements due to increased thyroxine-binding globulin, increased plasma volume, and placental deiodinase activity. Approximately 50-85% of patients require dose increases, often beginning at 4-8 weeks gestation. Starting dose increase: 30-50% increase in levothyroxine dose as soon as pregnancy confirmed. Monitor TSH every 4-6 weeks; adjust in increments of 12.5-25 mcg/day. Postpartum: dose typically returns to prepregnancy level within 4-6 weeks.
Pregnancy increases thyroid-binding globulin and plasma volume, leading to increased levothyroxine requirements. Dose often increases by 30-50% during pregnancy, starting as early as 4-6 weeks gestation. Frequent monitoring (every 4 weeks) and dose adjustments are necessary to maintain TSH in trimester-specific ranges: first trimester 0.1-2.5 m IU/L, second trimester 0.2-3.0 m IU/L, third trimester 0.3-3.0 m IU/L. Postpartum dose should be reduced to pre-pregnancy levels.
TIROSINT-SOL is a liquid formulation of levothyroxine sodium used for patients who cannot swallow tablets, have GI absorption issues, or require precise dosing. Administer on an empty stomach (30–60 minutes before breakfast) with water only. Avoid administration with iron, calcium, or antacids within 4 hours. Monitor TSH 4–6 weeks after dose changes. Use caution in patients with cardiovascular disease; start with low doses. T4 replacement may unmask adrenal insufficiency in panhypopituitarism—screen with ACTH stimulation test if suspected.
Levothyroxine (EUTHYROX) is the standard therapy for hypothyroidism. Absorption is reduced by calcium, iron, soy, and fiber; take on an empty stomach 30-60 minutes before breakfast. Dose adjustments needed in pregnancy, weight changes, and with interacting drugs (e.g., estrogens, rifampin, phenytoin). Monitor TSH 6-8 weeks after dose change. In hyperthyroidism, rapid levothyroxine withdrawal can precipitate thyroid storm; taper cautiously. For myxedema coma, use IV levothyroxine (not oral). When switching from a T3-containing preparation, cross-titration is required.
Take TIROSINT-SOL exactly as prescribed, usually once daily on an empty stomach, at least 30–60 minutes before eating or drinking anything except water.,Do not mix the solution with any other liquids or foods; only use the provided oral syringe for accurate dosing.,Inform your doctor if you are pregnant, planning pregnancy, or breastfeeding, as dose adjustments may be needed.,Do not stop taking this medication without consulting your doctor, even if you feel well; thyroid hormone replacement is usually lifelong.,Store the solution in the refrigerator (36°F to 46°F) and use within 60 days after first opening; do not freeze.
Take levothyroxine exactly as prescribed, at the same time each day.,Take on an empty stomach, at least 30-60 minutes before breakfast or any food.,Do not take with calcium supplements, iron supplements, antacids, or high-fiber foods; separate by at least 4 hours.,Do not stop or change dose without consulting your doctor.,If you miss a dose, take it as soon as you remember, but skip if it is almost time for the next dose; do not double dose.,Report symptoms of hyperthyroidism (rapid heart rate, palpitations, anxiety, weight loss) or hypothyroidism (fatigue, weight gain, cold intolerance).,Blood tests (TSH) will be done regularly to monitor dose.,Tell your doctor if you are pregnant, planning pregnancy, or breastfeeding.,Keep all medications out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TIROSINT-SOL vs EUTHYROX, answered by our medical review team.
TIROSINT-SOL is a Thyroid hormone replacement that works by Synthetic levothyroxine (T4) is deiodinated to triiodothyronine (T3), which binds to thyroid hormone receptors, activating gene transcription and increasing cellular metabolism.. EUTHYROX is a Thyroid Hormone Replacement that works by Synthetic levothyroxine is a T4 hormone that is converted to T3, binding to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate, cardiac output, and thermogenesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TIROSINT-SOL and EUTHYROX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TIROSINT-SOL is: Initial dose 1.6 mcg/kg orally once daily; adjust by 12.5-25 mcg increments every 4-6 weeks based on TSH; typical maintenance 100-125 mcg/day.. The standard adult dose of EUTHYROX is: Initial adult dose 25-50 mcg orally once daily; titrate by 12.5-25 mcg increments every 4-6 weeks; maintenance dose typically 100-200 mcg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TIROSINT-SOL and EUTHYROX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TIROSINT-SOL is classified as Category C. Levothyroxine (TIROSINT-SOL) is FDA Pregnancy Category A. No increased risk of fetal malformations when maternal hypothyroidism is treated. Untreated maternal hypothyroidism is ass. EUTHYROX is classified as Category C. EUTHYROX (levothyroxine) is a thyroid hormone replacement. Maternal hypothyroidism itself carries significant risks to the fetus, including neurodevelopmental deficits, preterm bir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.